- Home
- CPA vs GH Comparison
CPA vs GH Comparison
Compare CPA & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPA
- GH
- Stock Information
- Founded
- CPA 1947
- GH 2011
- Country
- CPA Panama
- GH United States
- Employees
- CPA N/A
- GH N/A
- Industry
- CPA Air Freight/Delivery Services
- GH Medical Specialities
- Sector
- CPA Consumer Discretionary
- GH Health Care
- Exchange
- CPA Nasdaq
- GH Nasdaq
- Market Cap
- CPA 3.6B
- GH 4.3B
- IPO Year
- CPA 2005
- GH 2018
- Fundamental
- Price
- CPA $92.21
- GH $38.39
- Analyst Decision
- CPA Strong Buy
- GH Strong Buy
- Analyst Count
- CPA 7
- GH 14
- Target Price
- CPA $156.14
- GH $39.93
- AVG Volume (30 Days)
- CPA 296.5K
- GH 1.8M
- Earning Date
- CPA 02-05-2025
- GH 02-20-2025
- Dividend Yield
- CPA 7.06%
- GH N/A
- EPS Growth
- CPA 62.61
- GH N/A
- EPS
- CPA 15.07
- GH N/A
- Revenue
- CPA $3,480,417,000.00
- GH $692,256,000.00
- Revenue This Year
- CPA $0.72
- GH $32.21
- Revenue Next Year
- CPA $6.95
- GH $16.90
- P/E Ratio
- CPA $5.85
- GH N/A
- Revenue Growth
- CPA 1.33
- GH 29.20
- 52 Week Low
- CPA $80.01
- GH $15.81
- 52 Week High
- CPA $114.00
- GH $39.29
- Technical
- Relative Strength Index (RSI)
- CPA 56.15
- GH 66.67
- Support Level
- CPA $85.27
- GH $34.80
- Resistance Level
- CPA $90.64
- GH $37.46
- Average True Range (ATR)
- CPA 2.31
- GH 1.78
- MACD
- CPA 0.63
- GH 0.51
- Stochastic Oscillator
- CPA 98.70
- GH 80.49
About CPA Copa Holdings S.A.
Copa Holdings SA is a provider of airline passenger and cargo services through its subsidiaries. The company operates through the air transportation segment. It offers international air transportation for passengers, cargo, and mail, operating from its Panama City hub in the Republic of Panama and domestic and international air transportation for passengers, cargo and mail with a point-to-point route network through Copa Colombia a Colombian air carrier. The company's geographical segments are North America, South America, Central America, and the Caribbean. It derives the maximum revenue from North America.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.